Compare Ishares Msci Brazil ETF (EWZ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs ResMed Inc. — how do they compare? Ishares Msci Brazil ETF trades at $43.47 (market cap $11.30B), while ResMed Inc. trades at $228.11 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 2.8× Ishares Msci Brazil ETF's market cap, and ResMed Inc. pays a 1.16% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and ResMed Inc. for 51 Days on average.
| EWZ | RMD | |
|---|---|---|
Market Cap | $11.30B | $31.89B |
Volume | 44,036,597 | 618,314 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $277.88 |
52-Week Low | $28.79 | $182.82 |
Typical Hold Time | 50 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $43.14, up 1.82% with strong bullish momentum from moving averages but overbought RSI signals. The ETF shows unusual options activity and institutional interest, driven by Brazil's upcoming election and commodity exposure. Recent news highlights Wall Street positioning for potential policy shifts under different election outcomes, with the fund serving as a diversification tool from U.S. tech concentration.
Outlook remains election-dependent with asymmetric upside potential through call options. Risks include political volatility, U.S.-Brazil trade tensions, and currency fluctuations. The technical setup suggests near-term consolidation near pivot points while fundamentals rely on Brazil's economic policies and commodity performance.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
